A review of halotherapy for chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is a chronic, progressive disease with symptoms of dyspnea, increased respiration rate, sputum production, and a reduced exercise intolerance.1 In 2008, the World Health Organization estimated that COPD was the tenth most prevalent cause for moderate to severe disability,2 and was the fourth leading cause of death, worldwide.3 With this significant burden, the impact of this disease on individuals, families’ quality of life, and the associated health care expense, COPD is recognized as an international health priority.

Rivista, Fonte: International Journal of COPD

A review of halotherapy for chronic obstructive pulmonary disease

Halotherapy improves the prognosis of acute respiratory distress syndrome and alleviated pyroptosis related biomarkers

Halotherapy relieves chronic obstructive pulmonary disease by alleviating NLRP3 inflammasome-mediated pyroptosis